Can serum apolipoprotein C-I demonstrate metabolic abnormality early in women with polycystic ovary syndrome?

Fertility and Sterility

Volumn 94, Issue 1, 2010, Pages 205-210

  Huang, Shuo ^a   Qiao, Jie ^a   Li, Rong ^a   Wang, Lina ^a   Li, Meizhi ^a  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

Author keywords

Apolipoprotein C I; insulin resistance; metabolism; polycystic ovary syndrome

Indexed keywords

ANDROGEN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN C1; C REACTIVE PROTEIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ANDROGEN BLOOD LEVEL; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CONTROLLED STUDY; DIET RESTRICTION; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; INSULIN RESISTANCE; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; APOLIPOPROTEIN C-I; BIOLOGICAL MARKERS; EARLY DIAGNOSIS; FEMALE; GLUCOSE; HUMANS; LIPID METABOLISM; POLYCYSTIC OVARY SYNDROME; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 77952543390     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2009.03.005     Document Type: Article

References (30)

1. Diamanti-Kandarakis E., Kouli C.R., Bergiele A.T., Filandra F.A., Tsianateli T.C., Spina G.G., et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 84 (1999) 4006-4011
2. Azziz R., Woods K.S., Reyna R., Key T.J., Knochenhauer E.S., and Yildiz B.O. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 89 (2004) 2745-2749
3. Legro R.S., Kunselman A.R., Dodson W.C., and Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 84 (1999) 165-169
4. Shaw L.J., Bairey Merz C.N., Azziz R., Stanczyk F.Z., Sopko G., Braunstein G.D., et al. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health-National Heart, Lung, and Blood Institute Sponsored Women's Ischemia Syndrome Evaluation. J Clin Endocrinol Metab 93 (2008) 1276-1284
5. Yarali H., Yildirir A., Aybar F., Kabakci G., Bukulmez O., Akgul E., et al. Diastolic dysfunction and increased serum homocysteine concentrations may contribute to increased cardiovascular risk in patients with polycystic ovary syndrome. Fertil Steril 76 (2001) 511-516
6. Dunaif A., Segal K.R., Futterweit W., and Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 38 (1989) 1165-1174
7. Legro R.S., Kunselman A.R., and Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med 111 (2001) 607-613
8. Zhao S., Qiao J., Li M., Zhang X.W., Yu J.K., and Li R. Discovery of distinct protein profiles for polycystic ovary syndrome with and without insulin resistance by surface-enhanced laser adsorption/ionization time of flight mass spectrometry. Fertil Steril 88 (2007) 145-151
9. Brewer H.B. Hypertriglyceridemia: changes in the plasma lipoproteins associated with an increased risk of cardiovascular disease. Am J Cardiol 83 (1999) 3-12
10. Shachter N.S. Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism. Curr Opin Lipidol 12 (2001) 297-304
11. Urbanek M., Legro R.S., Driscoll D.A., Azziz R., Ehrmann D.A., Norman R.J., et al. Thirty-seven candidate genes for polycystic ovary syndrome: strongest evidence for linkage is with follistatin. Proc Natl Acad Sci USA 96 (1999) 8573-8578
12. Shachter N.S., Ebara T., Ramakrishnan R., Steiner G., Breslow J.L., Ginsberg H.N., et al. Combined hyperlipidemia in transgenic mice overexpressing human apolipoprotein C1. J Clin Invest 98 (1996) 846-855
13. Phillips N.R., Waters D., and Havel R.J. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation 88 (1993) 2762-2770
14. Groot P.H., van Stiphout W.A., Krauss X.H., Jansen H., van Tol A., van Ramshorst E., et al. Postprandial lipoprotein metabolism in normolipidemic men with and without coronary artery disease. Arterioscler Thromb 11 (1991) 653-662
15. Ebara T., Conde K., Kako Y., Liu Y., Xu Y., Ramakrishnan R., et al. Delayed catabolism of ApoB-48 lipoproteins due to decreased heparan sulfate proteoglycan production in diabetic mice. J Clin Invest 105 (2000) 1807-1818
16. Koopmans S.J., Jong M.C., Que I., Pijl H., Radder J.K., Frolich M., et al. Hyperlipidemia is associated with increased insulin mediated glucose metabolism, reduced fatty acid metabolism and normal blood pressure in transgenic mice overexpressing human Apolipoproteins C1. Diabetologia 44 (2001) 437-443
17. The Rotterdam ESHRE/ASRM-Sponsored PCOS Work Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81 (2004) 19-25
18. Xing X.Y., Yang W.Y., and Yang Z.J. The diagnostic significance of homeostasis model assessment of insulin resistance in metabolic syndrome among subjects with different glucose tolerance. Chin J Diabetes 12 (2004) 182-186
19. Tai E.S., Lim S.C., Chew S.K., Tan B.Y., and Tan C.E. Homeostasis model assessment in a population with mixed ethnicity: the 1992 Singapore National Health Survey. Diabetes Res Clin Pract 49 (2000) 159-168
20. Jong M.C., Hofker M.H., and Havekes L.M. Role of apoCs in lipoprotein metabolism: Functional differences between apoC1, apoC2, and apoC3. Arterioscler Thromb Vasc Biol 19 (1999) 472-484
21. Jackson C.L., Bruns G.A.P., and Breslow J.L. Isolation and sequence of a human apolipoprotein CII cDNA clone and its use to isolate and map to human chromosome 19 the gene for apolipoprotein CII. Proc Natl Acad Sci USA 81 (1984) 2945-2949
22. Shachter N.S., Hayek T., Leff T., Smith J.D., Rosenberg D.W., Walsh A., et al. Overexpression of apolipoprotein C-II causes hypertriglyceridemia in transgenic mice. J Clin Invest 93 (1994) 1683-1690
23. Herbert P.N., Assmann G., Gotto Jr. A.M., and Frederickson D.S. Disorders of the lipoprotein and lipid metabolism. In: Stanbury J.B., Wyngaarden J.B., Frederickson D.S., Goldstein J.L., and Brown M.S. (Eds). The metabolic basis of inherited diseases. 5th ed (1983), McGraw-Hill, New York 589-651
24. de Silva H.V., Lauer S.J., Wang J., Simonet W.S., Weisgraber K.H., Mahley R.W., et al. Overexpression of human apolipoprotein C-III in transgenic mice results in an accumulation of apolipoprotein B48 remnants that is corrected by excess apolipoprotein E. J Biol Chem 269 (1994) 2324-2335
25. Shulman R.S., Herbert P.N., Wehrly K., and Fredrickson D.S. The complete amino acid sequence of C-I (ApoLp-Ser), an Apolipoprotein from human very low density lipoproteins. J Biol Chem 250 (1975) 182-190
26. Jong M.C., Gijbels M.J., Dahlmans V.E., Gorp P.J., Koopman S.J., Ponec M., et al. Hyperlipidemia and cutaneous abnormalities in transgenic mice overexpressing human Apolipoprotein C1. J Clin Invest 101 (1998) 145-152
27. Jong M.C., Dahlmans V.E., van Gorp P.J., van Dijk K.W., Breuer M.L., Hofker M.H., et al. In the absence of the low density lipoprotein receptor, human apolipoprotein C1 overexpression in transgenic mice inhibits the hepatic uptake of very low density lipoproteins via a receptor-associated protein-sensitive pathway. J Clin Invest 98 (1996) 2259-2267
28. Bjorkegren J., Boquist S., Samnegard A., Lundman P., Tornvall P., Ericsson C.G., et al. Accumulation of apolipoproteins C-I-rich and cholesterol-rich VLDL remnants during exaggerated postprandial triglyceridemia in normolipidemic patients with coronary artery disease. Circulation 101 (2000) 227-230
29. Bjorkegren J., Silveira A., Boquist S., Tang R., Karpe F., Bond M.G., et al. Postprandial enrichment of remnant lipoproteins with ApoC-I in healthy normolipidemic men with early asymptomatic atherosclerosis. Arterioscler Thromb Vasc Biol 22 (2002) 1470-1474
30. Cohn J.S., Tremblay M., Batal R., Jacques H., Veilleux L., Rodriguez C., et al. Plasma kinetics of VLDL and HDL ApoC-I in normolipidemic and hypertriglyceridemic subjects. J Lipid Res 43 (2002) 1680-1687